Realisation of established targets for patients with diabetes type 2 at primary care setting

Completed

• Conditions: Diabetes mellitus type II (DM type II); Nutritional, Metabolic, Endocrine; Non-insulin-dependent diabetes mellitus

• Registration Number: ISRCTN18435077
• Lead Sponsor: Aventis (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-12-19
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Patients with type 2 diabetes
2. Signed informed consent

Exclusion Criteria

1. Aged less than 18 years
2. Quality-adjusted life years (QALY) less than 5 years
3. Use of insulin, fibrates or thiazolidines less than 6 weeks before inclusion
4. Heart failure, New York Heart Association (NYHA) class II or more
5. Myocardial infarction (MI), angina pectoris (AP), transient ischaemic attack (TIA) or cerebrovascular attack (CVA) less than 3 months before randomisation
6. Surgery, severe trauma or infection less than 3 months before randomisation
7. Known liver disease or alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GT) greater than three times upper limit
8. Serum creatinine greater than 150 mmol/l
9. Triglycerides greater than 8 mmol/l

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The total amount of targets reached with treatment with rosiglitazone compared with treatment with no rosiglitazone.

Secondary Outcome Measures

Name	Time	Method
The outcome of glitazone on the recently discovered risk factors of diabetic patients.